| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $71,668 | 3 | 23 |
Sells | $725,569 | 10 | 77 |
| McArthur James G | President and CEO | 2 | $61,275 | 0 | $0 | $61,275 |
| STRECK PAUL | EVP, Head of R&D | 1 | $10,393 | 0 | $0 | $10,393 |
| DeLena Mary Beth | General Counsel | 0 | $0 | 1 | $2,406 | $-2,406 |
| Donnelly Noel | Chief Financial Officer | 0 | $0 | 1 | $2,565 | $-2,565 |
| Mellion Michelle L | Chief Medical Officer | 0 | $0 | 8 | $720,598 | $-720,598 |
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at PepGen Inc. have bought $71,668 and sold $725,569 worth of PepGen Inc. stock.
On average, over the past 5 years, insiders at PepGen Inc. have bought $14.47M and sold $553,564 worth of stock each year.
Highest buying activity among insiders over the last 12 months: McArthur James G (President and CEO) — $61,275. STRECK PAUL (EVP, Head of R&D) — $10,393.
The last purchase of 8,375 shares for transaction amount of $10,393 was made by STRECK PAUL (EVP, Head of R&D) on 2025‑05‑30.
| 2025-05-30 | STRECK PAUL | EVP, Head of R&D | 8,375 0.0218% | $1.24 | $10,393 | -5.11% | ||
| 2025-04-17 | McArthur James G | President and CEO | 10,000 0.0377% | $1.35 | $13,550 | +12.03% | ||
| 2025-04-08 | McArthur James G | President and CEO | 41,500 0.1327% | $1.15 | $47,725 | +48.00% | ||
| 2025-02-26 | Sale | Donnelly Noel | Chief Financial Officer | 1,527 0.005% | $1.68 | $2,565 | -1.96% | |
| 2025-02-26 | Sale | DeLena Mary Beth | General Counsel | 1,432 0.0047% | $1.68 | $2,406 | -1.96% | |
| 2024-07-25 | Sale | Mellion Michelle L | Chief Medical Officer | 7,571 0.0234% | $18.06 | $136,741 | -79.33% | |
| 2024-07-24 | Sale | Mellion Michelle L | Chief Medical Officer | 201 0.0006% | $18.01 | $3,619 | -78.53% | |
| 2024-07-18 | Sale | Mellion Michelle L | Chief Medical Officer | 12,625 0.0427% | $18.20 | $229,804 | -76.96% | |
| 2024-07-16 | Sale | Mellion Michelle L | Chief Medical Officer | 5,901 0.0194% | $18.00 | $106,247 | -78.72% | |
| 2024-07-12 | Sale | Mellion Michelle L | Chief Medical Officer | 3,288 0.0108% | $18.04 | $59,331 | -76.90% | |
| 2024-07-02 | Sale | Mellion Michelle L | Chief Medical Officer | 37 0.0001% | $18.07 | $669 | -75.03% | |
| 2024-07-01 | Sale | Mellion Michelle L | Chief Medical Officer | 875 0.0029% | $18.01 | $15,760 | -77.16% | |
| 2024-06-24 | Sale | Mellion Michelle L | Chief Medical Officer | 9,260 0.0291% | $18.19 | $168,427 | -76.43% | |
| 2024-06-12 | Sale | Mellion Michelle L | Chief Medical Officer | 1,086 0.0034% | $18.06 | $19,615 | -75.13% | |
| 2024-06-11 | Sale | Mellion Michelle L | Chief Medical Officer | 500 0.0016% | $18.04 | $9,022 | -75.22% | |
| 2024-06-06 | Sale | Mellion Michelle L | SVP, Clinical Development | 1,411 0.0045% | $18.00 | $25,398 | -74.05% | |
| 2024-06-05 | Sale | Mellion Michelle L | SVP, Clinical Development | 7,245 0.0223% | $18.09 | $131,062 | -75.06% | |
| 2024-05-17 | Sale | Svenstrup Niels | SVP, Chem. Mfg & Controls | 10,000 0.0306% | $13.41 | $134,100 | -57.22% | |
| 2024-02-09 | RA CAPITAL MANAGEMENT, L.P. | 2.56M 10.4935% | $10.64 | $27.21M | -33.63% | |||
| 2023-11-30 | McArthur James G | President and CEO | 1,694 0.006% | $4.17 | $7,056 | +115.10% |
| McArthur James G | President and CEO | 113913 0.3481% | $162,895.59 | 3 | 5 | +115.1% |
| STRECK PAUL | EVP, Head of R&D | 27805 0.085% | $39,761.15 | 1 | 0 | |
| Donnelly Noel | Chief Financial Officer | 1673 0.0051% | $2,392.39 | 0 | 1 | |
| DeLena Mary Beth | General Counsel | 1568 0.0048% | $2,242.24 | 0 | 1 | |
| Mellion Michelle L | Chief Medical Officer | 0 0% | $0 | 0 | 12 | |
| RA CAPITAL MANAGEMENT, L.P. | 9179273 28.0532% | $13.13M | 1 | 0 | <0.0001% | |
| Oxford Science Enterprises plc | 10 percent owner | 4755388 14.5332% | $6.8M | 1 | 0 | +7.35% |
| Shah Rajeev M. | 1302600 3.9809% | $1.86M | 1 | 0 | +7.35% | |
| Deerfield Private Design Fund V, L.P. | 476813 1.4572% | $681,842.59 | 1 | 0 | +7.35% | |
| KEATING LAURIE | director | 4166 0.0127% | $5,957.38 | 1 | 0 | <0.0001% |
| Svenstrup Niels | SVP, Chem. Mfg & Controls | 0 0% | $0 | 0 | 1 | |
| Goyal Jaya | EVP, Res. & Preclin. Dev. | 0 0% | $0 | 0 | 4 |
$4,613,182 | 103 | -36.00% | $52.13M | |
$77,062,892 | 41 | 13.96% | $40.17M | |
$6,787,959 | 35 | 49.84% | $45.36M | |
$23,895,365 | 34 | -37.28% | $36.83M | |
$459,011,221 | 33 | 33.04% | $45.76M | |
$241,165 | 22 | -16.72% | $46.48M | |
$167,476,357 | 20 | -1.54% | $54.21M | |
$20,234,041 | 17 | 2.09% | $37.93M | |
$28,281,140 | 14 | 18.42% | $50.12M | |
$932,835 | 14 | -19.33% | $51.39M | |
$232,423 | 8 | 14.22% | $47.54M | |
$8,470,804 | 6 | -13.28% | $41.91M | |
PepGen Inc. (PEPG) | $43,326,461 | 6 | 16.01% | $46.79M |
$119,593,679 | 6 | -21.91% | $48.38M | |
$149,996 | 5 | 16.26% | $39.64M | |
$195,184 | 5 | 6.34% | $51.81M | |
$26,254,149 | 5 | 49.97% | $47.15M | |
$67,369,250 | 3 | -22.09% | $37.63M | |
$32,000,000 | 3 | -41.00% | $49.58M |
| Increased Positions | 40 | +54.79% | 6M | +25.97% |
| Decreased Positions | 29 | -39.73% | 6M | -24.6% |
| New Positions | 23 | New | 4M | New |
| Sold Out Positions | 12 | Sold Out | 5M | Sold Out |
| Total Postitions | 84 | +15.07% | 25M | +1.37% |
| Ra Capital Management, L.P. | $16,996.00 | 32.39% | 10.69M | 0 | 0% | 2024-12-31 |
| Rtw Investments, Lp | $5,077.00 | 9.68% | 3.19M | +3M | New | 2024-12-31 |
| Viking Global Investors Lp | $2,357.00 | 4.49% | 1.48M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $2,058.00 | 3.92% | 1.29M | +8,127 | +0.63% | 2025-03-31 |
| Suvretta Capital Management, Llc | $1,867.00 | 3.56% | 1.17M | -486,611 | -29.3% | 2024-12-31 |
| Vanguard Group Inc | $1,451.00 | 2.77% | 912,670 | -6,745 | -0.73% | 2024-12-31 |
| Perceptive Advisors Llc | $1,319.00 | 2.51% | 829,536 | -580,902 | -41.19% | 2024-12-31 |
| Laurion Capital Management Lp | $1,289.00 | 2.46% | 810,761 | 0 | 0% | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $1,272.00 | 2.42% | 800,000 | -327,536 | -29.05% | 2024-12-31 |
| Orbimed Advisors Llc | $1,038.00 | 1.98% | 653,016 | -144,342 | -18.1% | 2024-12-31 |